Fostamatinib

Tavalisse

150 MG TabletCanadaMarketedAuthorised 10 Dec 2020

In other countries

The same active substances on other registers, the same brand first.

Documents

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Fostamatinib

Tavalisse

150 MG TabletCanadaMarketedAuthorised 10 Dec 2020

Open in the registerAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Documents

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

The official texts, at the regulator.

Register entryHealth Canada

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Health Canada, Canada

Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.

Licence: Open Government Licence Canada · Added 13 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Fostamatinib
Strength: 150 MG
Dosage form: Tablet
Route: Oral
Register: Canada (Health Canada)
Status: Marketed
Authorised: 10 Dec 2020
Registration: DIN 02508060
Marketing authorisation holder: Medison Pharma Canada INC.
ATC code: B02BX09
Group: Blood and blood-forming organs
Supply: PRESCRIPTION